Dr Iza Denis
Dr Iza Denis is a National Breast Cancer Foundation of Australia Fellow at the Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide. In 2009 Dr Denis completed a Bachelor in Life and Earth Sciences at the University of Rennes, France. In 2009, she undertook a Master’s program in Regenerative Medicine (funded by an ERASMUS scholarship) at the DNA damage response laboratory, National University of Galway Ireland (NUIG). Her research project was focused on elucidating cytoplasmic and nuclear signalling in response to chemotherapeutic drugs in human breast cancer cells. Dr Denis subsequently (2010) undertook an additional MSc program in Cellular Biology and Physiopathology at the University Victor Segalen of Bordeaux, France, during which she studied the role of the CXCL4 chemokine and a CXCL4 variant, CXCL4L1, in cancer-related angiogenesis. In 2014 she was awarded her PhD at the University of Nantes Cancer Research Institute, France. The focus of her PhD studies was developing new therapeutic approaches to treat mesothelioma and lung cancer, utilising nanomedicine, new epigenetic drugs and immunogenic strategies. Dr Denis has published 8 original research papers (4 as first author).
|2017||Das, R., Gregory, P., Fernandes, R., Denis, I., Wang, Q., Townley, S. ... Butler, L. (2017). MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2. Cancer Research, 77, 4, 1021-1034.
|2016||Bahhaj, F. E., Denis, I., Pichavant, L., Delatouche, R., Collette, F., Linot, C. ... Bertrand, P. (2016). Histone Deacetylase Inhibitors Delivery using Nanoparticles with Intrinsic Passive Tumor Targeting Properties for Tumor Therapy. Theranostics, 6, 6, 795-807.
|2015||Denis, I., el Bahhaj, F., Collette, F., Delatouche, R., Gueugnon, F., Pouliquen, D. ... Blanquart, C. (2015). Histone deacetylase inhibitor-polymer conjugate nanoparticles for acid-responsive drug delivery. European Journal of Medicinal Chemistry, 95, 369-376.
|2014||Denis, I., Cellerin, L., Gregoire, M. & Blanquart, C. (2014). Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma. Oncotarget, 5, 22, 11641-11652.
|2014||Zwick, V., Chatzivasileiou, A. -. O., Deschamps, N., Roussaki, M., Simões-Pires, C. A., Nurisso, A. ... Cuendet, M. (2014). Aurones as histone deacetylase inhibitors: Identification of key features. Bioorganic & Medicinal Chemistry Letters, 24, 23, 5497-5501.
|2014||Denis, I., el Bahhaj, F., Collette, F., Delatouche, R., Gueugnon, F., Pouliquen, D. ... Blanquart, C. (2014). Vorinostat–Polymer Conjugate Nanoparticles for Acid-Responsive Delivery and Passive Tumor Targeting. Biomacromolecules, 15, 12, 4534-4543.
|2013||Delatouche, R., Denis, I., Grinda, M., Bahhaj, F. E., Baucher, E., Collette, F. ... Bertrand, P. (2013). Design of pH responsive clickable prodrugs applied to histone deacetylase inhibitors: A new strategy for anticancer therapy. European Journal of Pharmaceutics and Biopharmaceutics, 85, 3, 862-872.
|2013||Gueugnon, F., Denis, I., Pouliquen, D., Collette, F., Delatouche, R., Héroguez, V. ... Blanquart, C. (2013). Nanoparticles Produced by Ring-Opening Metathesis Polymerization Using Norbornenyl-poly(ethylene oxide) as a Ligand-Free Generic Platform for Highly Selective In Vivo Tumor Targeting. Biomacromolecules, 14, 7, 2396-2402.